Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8334585 | 0.89 | PRSS1 (0.49) | HDAC1PRSS1HDAC3NCOR2 | |
| SCHEMBL23963004 | 0.85 | HDAC1 (0.50) | HDAC1PRSS1HDAC3NCOR2HDAC2 | |
| SCHEMBL4054487 | 0.81 | HDAC1 (0.44) | HDAC1PRSS1HDAC3NCOR2HDAC2 | |
| SCHEMBL5225550 | 0.81 | SHMT2 (0.44) | PIK3CA | |
| SCHEMBL2927441 | 0.81 | PRSS1 (0.49) | PRSS1PTGER4 | |
| SCHEMBL29126106 | 0.80 | HDAC1 (0.51) | HDAC1PRSS1HDAC3NCOR2HDAC2 | |
| SCHEMBL6571157 | 0.78 | TDO2 (0.38) | HDAC1PRSS1HDAC2 | |
| SCHEMBL7088249 | 0.78 | SMN1; SMN2 (0.44) | HDAC1PRSS1HDAC3 | |
| SCHEMBL18208607 | 0.78 | KMT2A (0.44) | PIK3CA | |
| SCHEMBL10182367 | 0.78 | PRSS1 (0.46) | PRSS1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456293-B2 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SK HOLDING CO., LTD (KR) | 2008-11-25 | — | — | US | disclosed |
| EP-1869004-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS, THEIR PREPARATION AND USE | SK Holdings Co., Ltd. (KR) | 2007-12-26 | — | — | EP | disclosed |
| US-20060281802-A1 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-12-14 | — | — | US | disclosed |
| WO-2006104349-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS, THEIR PREPARATION AND USE | SK HOLDINGS CO., LTD. (KR) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281802-A1 | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | SLC5A1, CPT1A, GPR119 | HDAC1 995/4885PRSS1 2974/4885HDAC3 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.